Table 2. Patient characteristics according to the prognostic group defined by the gene-expression predictor.
Clinical and treatment characteristics were compared using Fisher’s exact test.
| high-risk N=122 no./total no. (%)* |
low-risk N=338 no./total no. (%)* |
P-value | |
|---|---|---|---|
|
| |||
| Cohort | |||
| 1 = PRIMA trial | 59/122 (48) | 113/338 (33) | |
| 2 = UI/MC - SPORE cohort | 42/122 (34) | 144/338 (43) | |
| 3 = BCN | 21/122 (17) | 81/338 (24) | |
|
| |||
| Baseline characteristics | |||
| Age > 60 years | 31/122 (25) | 134/338 (40) | 0.0050 |
| Male sex | 69/122 (57) | 168/338 (50) | 0.194 |
| Ann Arbor stage III/IV | 111/120 (93) | 273/338 (81) | 0.0027 |
| ECOG PS ≥ 1 | 45/121 (37) | 86/337 (26) | 0.015 |
| B symptoms present | 41/121 (34) | 67/336 (20) | 0.0080 |
| Bone Marrow involvement | 95/116 (82) | 152/324 (47) | <0.0001 |
| Elevated LDH | 42/111 (38) | 99/315 (31) | 0.217 |
| Hemoglobin level < 12 g/dL | 28/114 (25) | 55/321 (17) | 0.083 |
| Elevated β2-microglobulin | 53/80 (66) | 120/214 (56) | 0.115 |
|
| |||
| FLIPI score | |||
| 0-1 risk factors | 19/120 (16) | 111/333 (33) | |
| 2 risk factors | 42/120 (35) | 108/333 (32) | 0.0006 |
| 3-5 risk factors | 59/120 (49) | 114/333 (34) | |
|
| |||
| Histological grade | |||
| 1-2 | 102/122 (84) | 217/338 (64) | |
| 3A | 16/122 (13) | 97/338 (29) | 0.0004 |
| Undetermined/other** | 4/122 (3) | 24/338 (7) | |
|
| |||
| Induction regimen | |||
| R-CHOP | 90/122 (74) | 265/338 (78) | |
| R-CVP | 21/122 (17) | 53/338 (16) | 0.596 |
| R-Bendamustine | 10/122 (8) | 19/338 (6) | |
| other | 1/122 (1) | 1/338 (0) | |
|
| |||
| Maintenance regimen | |||
| No | 79/122 (65) | 228/338 (67) | 0.587 |
| Yes | 43/122 (35) | 110/338 (33) | |
*
Because of rounding, percentages may not total 100.
**
Undetermined/other included FL of undetermined grade (except 3B, n=16), FL with component DLBCL<10% (n=10) and FL with diffuse area (n=2).